Louisiana State Employees Retirement System reduced its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 6.0% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,900 shares of the biotechnology company’s stock after selling 700 shares during the period. Louisiana State Employees Retirement System’s holdings in United Therapeutics were worth $1,613,000 as of its most recent SEC filing.
Other institutional investors also recently bought and sold shares of the company. Quantbot Technologies LP grew its holdings in shares of United Therapeutics by 537.3% during the 3rd quarter. Quantbot Technologies LP now owns 975 shares of the biotechnology company’s stock valued at $114,000 after acquiring an additional 822 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. bought a new stake in United Therapeutics in the third quarter worth $156,000. Toronto Dominion Bank boosted its holdings in United Therapeutics by 244.7% in the third quarter. Toronto Dominion Bank now owns 1,903 shares of the biotechnology company’s stock worth $223,000 after purchasing an additional 1,351 shares in the last quarter. Meiji Yasuda Asset Management Co Ltd. bought a new stake in United Therapeutics in the third quarter worth $233,000. Finally, TLP Group LLC bought a new stake in United Therapeutics in the second quarter worth $246,000.
A number of equities research analysts recently issued reports on the stock. Credit Suisse Group reiterated an “underperform” rating and issued a $118.00 price objective on shares of United Therapeutics in a report on Thursday. TheStreet cut shares of United Therapeutics from a “b-” rating to a “c” rating in a report on Friday, September 29th. Zacks Investment Research upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating and set a $160.00 price objective for the company in a report on Monday, January 15th. BidaskClub cut shares of United Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, January 16th. Finally, Oppenheimer upped their price objective on shares of United Therapeutics to $180.00 and gave the stock an “outperform” rating in a report on Friday, January 5th. Four equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $140.27.
United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $4.01 by $2.26. The firm had revenue of $445.50 million during the quarter, compared to analyst estimates of $426.43 million. United Therapeutics had a net margin of 30.50% and a return on equity of 26.24%. The business’s revenue was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $4.23 EPS. equities research analysts anticipate that United Therapeutics Co. will post 12.96 earnings per share for the current year.
In other United Therapeutics news, Director Christopher Causey sold 580 shares of the business’s stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $134.72, for a total transaction of $78,137.60. Following the completion of the transaction, the director now owns 1,555 shares of the company’s stock, valued at approximately $209,489.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 1,269 shares of the business’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $118.04, for a total transaction of $149,792.76. Following the transaction, the chief executive officer now directly owns 1,409 shares of the company’s stock, valued at approximately $166,318.36. The disclosure for this sale can be found here. In the last three months, insiders have sold 14,508 shares of company stock valued at $1,774,621. Company insiders own 7.80% of the company’s stock.
About United Therapeutics
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.